Idenix receives EU approval for hepatitis drug
Idenix plans to launch the once-a-day oral treatment for adult patients with chronic hepatitis B in the second quarter of 2007 beginning with the UK and Germany. In
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.